Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Pfizer and Blackstone Life Sciences announced a strategic co-funding agreement where Blackstone will provide up to $ 1.5 billion through 2028 for the development of the obesity drug berobenatide.
- In exchange for the funding, Blackstone is eligible for milestone-based payments tied to U.S. regulatory approval and commercial sales milestones.…
Disclaimer

Pfizer Inc. (NYSE:PFE) and Blackstone Life Sciences on Wednesday announced a strategic co-funding agreement under which Blackstone will pay up to $1.5 billion in development costs through 2028 for berobenatide.

Regulatory Approval and Commercial Sales Milestone Terms

The investigational drug is a potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.

In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and achievement of certain commercial sales milestones.

Read Also: Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance

Pfizer Planned 20-Plus Trials for Obesity, Related Conditions in 2026

This includes 10 ongoing and planned Phase 3 trials for berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide being studied for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea.

The growing body of evidence supports advancing an extensive development program for berobenatide as a monotherapy and in combination with various Nutrient-Stimulated Hormone (NuSH) peptides, including amylin analogs.

Encouraging Phase 2 Study Data

In June, Pfizer shared data from Phase 2b studies of berobenatide.

The company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants.

Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide.

The VESPER-6 pivotal Phase 3 study investigating monthly maintenance dosing for berobenatide in obese adults is open for enrollment, as well as the SOLIS-1 Phase 2b study investigating weekly and monthly maintenance dosing of an ultra-long-acting amylin analog (PF’3945) as a monotherapy and in combination with berobenatide.

PFE Price Action: Pfizer shares were up 0.44% at $29.58 during premarket trading on Thursday, according to Benzinga Pro data.

Read Also: Warren Buffett’s 1979 Warning May Be the Perfect Lesson for Today’s AI Boom, Says Howard Marks: ‘Uncertainty Actually is the Friend’

Image via Shutterstock

Login to unlock1,691characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.